Results 331 to 340 of about 22,453,438 (395)

The Interleukin -2

Acta Clinica Belgica, 1987
SummaryDiscovered in 1976, the lymphokine interleukin-2, intensively studied during the last years, plays a major role in the regulation of the immune function. The authors reviewing its principal properties, anticipate forthcoming prospects of considerable implications in therapy.Acta Clin. Bclg. 42, 4: 255–68.
M. Hiden, P. Neve
openaire   +3 more sources

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

New England Journal of Medicine, 1987
We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus interleukin-2 or therapy with high-dose interleukin-2 alone in 157 patients with metastatic cancer for whom standard therapy had proved ineffective or no ...
S. Rosenberg, M. Lotze, L. Muul, A. E. Chang, F. Avis, S. Leitman, W. Linehan, C. Robertson, R. Lee, J. Rubin, C. Seipp, Colleen G. Simpson, D. White   +12 more
semanticscholar   +1 more source

Interleukin-2 toxicity. [PDF]

Journal of Clinical Oncology, 1991
Because of the ability of interleukin-2 (IL-2) to support the proliferation and activation of numerous types of immunocompetent cells and to support the survival of adoptively transferred lymphocytes, there has been considerable interest in its use in the immunotherapy of malignancies.
Jay P. Siegel, Roj K. Puri
openaire   +2 more sources

Regulation of Interleukin 2 Receptor Expression by Interleukin 2

Scandinavian Journal of Immunology, 1986
The regulatory influence of Interleukin 2 (IL‐2) on the expression of IL‐2 receptors (IL.‐2R) was studied using long‐term cultured T‐cell lines and recombinant IL‐2 (r‐IL‐2). Three T‐cell lines with different growth requirements were used as model systems: insulin‐specific BK‐BI‐1.2 cells express IL‐2R transiently after antigenic restimulation ...
T. Diamantstein, A. B. Reske‐Kunz, D. Steldern, E. Rüde   +3 more
openaire   +3 more sources

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

New England Journal of Medicine, 1985
We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer.
S. Rosenberg, M. Lotze, L. Muul, S. Leitman, A. E. Chang, S. Ettinghausen, Y. Matory, J. Skibber, E. Shiloni, J. Vetto, C. Seipp, Colleen G. Simpson, C. Reichert   +12 more
semanticscholar   +1 more source

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

New England Journal of Medicine, 1988
Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of
S. Rosenberg, B. S. Packard, P. Aebersold, D. Solomon, S. Topalian, S. T. Toy, P. Simon, M. Lotze, James C. Yang, C. Seipp, Colleen G. Simpson, C. Carter, S. Bock, D. Schwartzentruber, John P. Wei, D. White   +15 more
semanticscholar   +1 more source

Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis.

American Review of Respiratory Disease, 2015
Using a human T-cell line sensitive to interleukin-2 (IL-2), we evaluated supernatants of unstimulated, purified lung T-lymphocytes from patients with sarcoidosis and high-intensity alveolitis (active disease), patients with sarcoidosis and low-intensity
G. Hunninghake, G. Bedell, D. Zavala, M. Monick, M. Brady   +4 more
semanticscholar   +1 more source

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Journal of Clinical Oncology, 1999
PURPOSE To determine the short- and long-term efficacy and toxicity of the high-dose intravenous bolus interleukin 2 (IL-2) regimen in patients with metastatic melanoma.
M. Atkins, M. Lotze, J. Dutcher, R. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, S. Rosenberg   +12 more
semanticscholar   +1 more source

Interleukin-2

Annual Review of Immunology, 1984
In the past year there have been significant advances in understanding the role of interleukin-2. Its role in the activation of T cells by antigen-presenting cells, the structure-activity relationships between interleukin-2 and its receptor and the subsequent signaling have all become clearer.
openaire   +4 more sources

Interleukin-2: inception, impact, and implications.

Science, 1988
Interleukin-2 (IL-2), the first of a series of lymphocytotrophic hormones to be recognized and completely characterized, is pivotal for the generation and regulation of the immune response.
Kendall A. Smith
semanticscholar   +1 more source